ba0003pp27 | Bone biomechanics and quality | ECTS2014
Cabal Antonio
, Jayakar Richa Y
, Zhang Jingru
, Sardesai Swanand
, Williams Donald S
, Duong Le T
The cathepsin K inhibitor odanacatib (ODN) is a bone formation-sparing inhibitor of osteoclastic resorption activity. This drug is currently under development for the treatment of postmenopausal osteoporosis. To support the bone safety profile of ODN, we evaluated the effects of ODN on trabecular bone hard tissue properties in the estrogen-deficient model of the ovariectomized (OVX) rhesus monkeys. Animals (n=16/group, age 1122 years) were treated immediately af...